Maat Pharma SA (PA:MAAT) — Market Cap & Net Worth
Market Cap & Net Worth: Maat Pharma SA (MAAT)
Maat Pharma SA (PA:MAAT) has a market capitalization of $35.73 Million (€30.56 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #23277 globally and #363 in its home market, demonstrating a -41.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Maat Pharma SA's stock price €1.63 by its total outstanding shares 18751521 (18.75 Million). Also see MAAT total assets for a full breakdown of the balance sheet.
Maat Pharma SA Market Cap History: 2021 to 2026
Maat Pharma SA's market capitalization history from 2021 to 2026. Data shows change from $292.67 Million to $35.73 Million (-35.69% CAGR). Also see MAAT operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Maat Pharma SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Health Care
FRHC
|
$239.52 Billion | 0.01% | #28 of 36 |
Weight: Maat Pharma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Maat Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Maat Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Maat Pharma SA share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
54.26x
Maat Pharma SA's market cap is 54.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $292.67 Million | $972.00K | -$9.02 Million | 301.10x | N/A |
| 2022 | $175.38 Million | $1.43 Million | -$13.71 Million | 122.64x | N/A |
| 2023 | $153.02 Million | $2.23 Million | -$19.72 Million | 68.68x | N/A |
| 2024 | $174.50 Million | $3.22 Million | -$28.90 Million | 54.26x | N/A |
Competitor Companies of MAAT by Market Capitalization
Companies near Maat Pharma SA in the global market cap rankings as of September 20, 2026. Review MAAT intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Maat Pharma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Maat Pharma SA Historical Marketcap From 2021 to 2026
Between 2021 and today, Maat Pharma SA's market cap moved from $292.67 Million to $ 35.73 Million, with a yearly change of -35.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €35.73 Million | -66.11% |
| 2025 | €105.45 Million | -39.57% |
| 2024 | €174.50 Million | +14.04% |
| 2023 | €153.02 Million | -12.75% |
| 2022 | €175.38 Million | -40.07% |
| 2021 | €292.67 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Maat Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.73 Million USD |
| MoneyControl | $35.73 Million USD |
| MarketWatch | $35.73 Million USD |
| marketcap.company | $35.73 Million USD |
| Reuters | $35.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more